LBA-3: BRUIN CLL-313: Pirtobrutinib is superior to bendamustine plus rituximab in treatment-naïve CLL/SLL

EHA 2026

Leukemia

LB5001: BRUIN CLL-322: Fixed-duration pirtobrutinib plus venetoclax-rituximab outperforms venetoclax plus rituximab in patients with R/R CLL

Leukemia

BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

J Clin Oncol

Jurczak W, Kwiatek M, Czyz J, Roberto de Mattos E, Eom KS, Egle A, Panovska A, Popova ZG, Shih HJ, Casado Montero LF, Sportoletti P, Hua VM, D'Olimpio JT, Iida S, Ito R, Bao K, Fink A, Su W, Ruppert AS, Levy A, Wrobel T

doi: 10.1200/JCO-25-02380

Leukemia

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial

Lancet

Davids MS, Eyre TA, Woyach JA, Roeker LE, Ferrajoli A, Wang Y, Tam CS, Jurczak W, Zinzani PL, Šimkovič M, Li JY, Bosch F, Roos-Weil D, Cramer P, Osterborg A, Islam P, Jacobs R, Skarbnik A, Bhat SA, Kang S, Chen M, Nguyen B, McNeely SC, Chung KL, Oliveira JM, Ito R, Ghia P, Wierda WG

doi: 10.1016/S0140-6736(26)01204-3

ASH 2025

BRUIN CLL-314: Pirtobrutinib demonstrates noninferior ORR versus ibrutinib in the first head-to-head trial in BTKi-naïve patients with CLL/SLL

Leukemia

A comprehensive analysis of pirtobrutinib in Chinese patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): Results from the phase 3 study BRUIN CLL-321

Br J Haematol

Yi S, Cao J, Feng R, Zhou K, Qiu L, Li F, Yang HY, Zhou H, Hui W, Cui J, Huang H, Zhu J, Ye X, Sharman J, Qiu L

doi: 10.1111/bjh.70334

ASH 2025

Leukemia

AMPLIFY: Manageable safety profile of acalabrutinib plus venetoclax with or without obinutuzumab in patients with treatment-naïve CLL

CHICAGO 2026

Lung, Respiratory and Thoracic Cancer

IMforte: Superior quality-adjusted survival with lurbinectedin plus atezolizumab maintenance in treatment-naïve patients with ES-SCLC

ASH 2025

Multiple Myeloma (MM)

LBA-6: MajesTEC-3: Unprecedented outcomes reinforce teclistamab plus daratumumab as a potential new standard of care for RRMM

Leukemia

Hypertension and time to treatment failure with acalabrutinib and ibrutinib in treatment-naïve CLL/SLL

Leuk Lymphoma

Narkhede MS, Blau S, Peevyhouse A, Neuhalfen H, Dietz LA, Huynh C, Wahlstrom SK, Teschemaker A, Shetty V, Dranitsaris G, Ermann D

doi: 10.1080/10428194.2026.2687635

Related content

LB5001: BRUIN CLL-322: Fixed-duration pirtobrutinib plus venetoclax-rituximab outperforms venetoclax plus rituximab in patients with R/R CLL

BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial

BRUIN CLL-314: Pirtobrutinib demonstrates noninferior ORR versus ibrutinib in the first head-to-head trial in BTKi-naïve patients with CLL/SLL

A comprehensive analysis of pirtobrutinib in Chinese patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): Results from the phase 3 study BRUIN CLL-321

AMPLIFY: Manageable safety profile of acalabrutinib plus venetoclax with or without obinutuzumab in patients with treatment-naïve CLL

IMforte: Superior quality-adjusted survival with lurbinectedin plus atezolizumab maintenance in treatment-naïve patients with ES-SCLC

LBA-6: MajesTEC-3: Unprecedented outcomes reinforce teclistamab plus daratumumab as a potential new standard of care for RRMM

Hypertension and time to treatment failure with acalabrutinib and ibrutinib in treatment-naïve CLL/SLL